Page last updated: 2024-12-05

diflunisal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce fever. It is a derivative of salicylic acid and is thought to work by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. Diflunisal is available by prescription only. It is typically taken orally, usually two to four times a day. Common side effects include nausea, heartburn, stomach pain, and dizziness. Diflunisal can also cause more serious side effects, such as bleeding in the stomach or intestines, liver damage, and kidney problems. It is important to talk to your doctor about the risks and benefits of taking diflunisal.'

Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3059
CHEMBL ID898
CHEBI ID39669
SCHEMBL ID4337
MeSH IDM0006367

Synonyms (165)

Synonym
BIDD:GT0063
MLS001146895
AB00051969-12
BRD-K22031190-001-05-3
[1,1'-biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-
MLS000028678 ,
DIVK1C_000938
KBIO1_000938
dolobid
mk-647
2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid
reuflos
brn 2654431
fluniget
adomal
2',4'-difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid
unisal
diflunisalum [inn-latin]
mk 647
einecs 245-034-9
algobid
dolobis
flustar
fluodonil
flovacil
noaldol
citidol
(1,1'-biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-
3-biphenylcarboxylic acid, 2',4'-difluoro-4-hydroxy-
dolobid (tn)
D00130
diflunisal (jan/usp/inn)
SPECTRUM_000962
PRESTWICK_168
cas-22494-42-4
NCGC00016765-01
BSPBIO_002203
PRESTWICK3_000039
PRESTWICK2_000039
IDI1_000938
BSPBIO_000137
SPECTRUM5_000901
AB00051969
22494-42-4
C01691
diflunisal
2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid
CHEBI:39669 ,
5-(2,4-difluorophenyl)salicylic acid
DB00861
1FL ,
5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid
BPBIO1_000151
NCGC00022783-03
NCGC00022783-04
smr000058723
KBIO2_004010
KBIOSS_001442
KBIO3_001423
KBIOGR_001085
KBIO2_001442
KBIO2_006578
SPBIO_001163
SPECTRUM2_001012
NINDS_000938
SPECTRUM4_000513
PRESTWICK0_000039
SPECTRUM3_000392
PRESTWICK1_000039
SPBIO_002058
SPECTRUM1500245
NCGC00016765-02
mk647
HMS2090C16
HMS2091M20
bdbm50240510
nsc-756728
CHEMBL898 ,
5-[2,4-difluorophenyl]salicylic acid
HMS502O20
HMS1920G10
HMS1568G19
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
HMS2095G19
HMS3259G17
AKOS005762917
A816230
5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid;diflunisal
pharmakon1600-01500245
nsc756728
dtxsid5022932 ,
tox21_110598
dtxcid702932
S4609
CCG-40230
NCGC00016765-05
NCGC00016765-04
NCGC00016765-03
NCGC00016765-06
diflunisalum
unii-7c546u4den
7c546u4den ,
nsc 756728
diflunisal [usan:usp:inn:ban:jan]
dolobil
difludol
dolisal
FT-0630487
diflunisal [usp monograph]
diflunisal [usan]
diflunisal [vandf]
diflunisal [mi]
diflunisal [inn]
diflunisal [ep impurity]
diflunisal [orange book]
diflunisal [who-dd]
diflunisal [mart.]
diflunisal [jan]
diflunisal [usp impurity]
diflunisal [usp-rs]
gtpl7162
NC00506
SCHEMBL4337
tox21_110598_1
NCGC00016765-09
KS-1346
diflusinal
2',4'-difluoro-4-hydroxybipheny-3-carboxylic acid
2',4'-difluoro-4-hydroxy-biphenyl-3-carboxylic acid
2',4'-difluoro-4-hydroxy-(1',1-diphenyl)-3-carboxylic acid
AB00051969_13
OPERA_ID_803
mfcd00057834
2',4'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid
SR-01000003165-2
sr-01000003165
diflunisal, united states pharmacopeia (usp) reference standard
diflunisal, analytical standard
diflunisal, european pharmacopoeia (ep) reference standard
J-014739
SR-01000003165-3
SBI-0051347.P003
HMS3712G19
HY-18342
1286107-99-0
CS-0007468
NCGC00016765-08
Q2602750
BCP09905
BRD-K22031190-001-13-7
HMS3885H10
EN300-3232727
2 inverted exclamation mark ,4 inverted exclamation mark -difluoro-4-hydroxybiphenyl-3-carboxylic acid
SY106650
D5875
diflunisal (ep impurity)
diflunisalum (inn-latin)
diflunisal (usan:usp:inn:ban:jan)
n02ba11
diflunisal (mart.)
diflunisal (usp impurity)
diflunisal (usp monograph)
diflunisal (usp-rs)

Research Excerpts

Overview

Diflunisal is a long-acting non-steroidal anti-inflammatory drug (NSAID) most commonly used to treat acute postoperative pain or chronic joint pain from osteoarthritis and rheumatoid arthritis. The drug is an effective analgesic and also has anit-inflammatory action.

ExcerptReferenceRelevance
"Diflunisal is an approved non-steroidal anti-inflammatory drug that stabilizes TTR, with limited data available regarding effects on cardiac structure and function."( Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis.
Berk, JL; Connors, LH; Fox, J; Gopal, DM; Hellawell, J; Lohrmann, G; Maurer, MS; Mussinelli, R; Pipilas, A; Ruberg, FL; Siddiqi, OK; Vellanki, N, 2020
)
1.55
"Diflunisal is a NSAID used in acute and long term management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis and symptoms of primary dysmenorrhea. "( An insight on human skin penetration of diflunisal: lipogel versus hydrogel microemulsion.
Mortada, SM; Motawaa, AM; Sallam, MA, 2015
)
2.13
"Diflunisal is a long-acting non-steroidal anti-inflammatory drug (NSAID) most commonly used to treat acute postoperative pain or chronic joint pain from osteoarthritis and rheumatoid arthritis. "( Single dose oral diflunisal for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA; Wasey, JO, 2010
)
2.14
"Diflunisal is a new salicylic acid derivative identified after a search for a compound with improved potency, enhanced gastrointestinal tolerance relative to its antiinflammatory activity, and a longer duration of action than that of aspirin. "( Review of the animal and clinical pharmacology of diflunisal.
Davies, RO,
)
1.83
"Diflunisal is a salicylic acid derivative with analgesic and anti-inflammatory activity. "( Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis.
Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980
)
3.15
"Diflunisal is an effective analgesic and also has anit-inflammatory action."( Diflunisal in rheumatoid arthritis. A controlled trial.
Schorn, D, 1981
)
2.43
"Diflunisal is a difluorophenyl derivative of salicylic acid. "( Selective adverse reactions to diflunisal.
Arias, J; Fernández-Rivas, M; García, MA; Moral, A; Senent, CJ, 1995
)
2.02
"Diflunisal is a nonsteroidal anti-inflammatory drug that is poorly soluble in water. "( Dissolution kinetics for coprecipitates of diflunisal with PVP K30.
Goñi, MM; Martín, C; Martínez-Ohárriz, MC; Rodríguez-Espinosa, C; Sánchez, M; Vélaz, I,
)
1.84
"Diflunisal was found to be an effective analgesic in mild to moderate pain of acute soft tissue injuries, and caused fewer and more tolerable side effects than did acetaminophen with codeine."( Treatment of mild to moderate pain of acute soft tissue injury: diflunisal vs acetaminophen with codeine.
DeForge, B; King, DE; Muncie, HL, 1986
)
1.23
"Diflunisal is an alternative capable of improving the painful stiffness associated with AS."( A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis.
Franssen, MJ; Gribnau, FW; van de Putte, LB, 1986
)
1.34
"Diflunisal is a salicylate derivative with analgesic and anti-inflammatory properties. "( Assay methodology for quantification of the ester and ether glucuronide conjugates of diflunisal in human urine.
Lin, JH; Lyon, KA; Musson, DG; Tocco, DJ; Yeh, KC, 1985
)
1.94

Effects

Diflunisal has an analgesic effect similar to other NSAIDs in single dose, but benefits from providing significant analgesia for about twelve hours. Difl unisal has shown a slightly more powerful and larger lasting antalgic action than the drug which was used as a comparison.

ExcerptReferenceRelevance
"Diflunisal has an analgesic effect similar to other NSAIDs in single dose, but benefits from providing significant analgesia for about twelve hours. "( Single dose oral diflunisal for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA; Wasey, JO, 2010
)
2.14
"Diflunisal (DIF) has analgesic and anti-inflammatory activity. "( Separation and Determination of Diflunisal and its Impurity by Two Chromatographic Methods: TLC-Densitometry and HPLC.
El Ghobashy, MR; Farid, NF; Moatamed, RS; Naguib, IA, 2021
)
2.35
"Diflunisal has an analgesic effect similar to other NSAIDs in single dose, but benefits from providing significant analgesia for about twelve hours. "( Single dose oral diflunisal for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA; Wasey, JO, 2010
)
2.14
"Diflunisal has however shown a slightly more powerful and larger lasting antalgic action which provides a higher tolerance level than the drug which was used as a comparison."( [Use of NSAIDS in dentistry: double blind controlled study of Diflunisal versus ASA].
Bonucci, I; Capuano, A; Rosadini, F; Valerio, P,
)
1.09

Actions

ExcerptReferenceRelevance
"Diflunisal is known to inhibit S."( Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus Osteomyelitis.
Cassat, JE; Guelcher, SA; Hammer, ND; Hendrix, AS; Putnam, NE; Skaar, EP; Snyder, DJ; Spoonmore, TJ; Wilde, AD, 2016
)
1.41

Treatment

ExcerptReferenceRelevance
"Treatment with diflunisal 30 minutes after completion of surgery proved to be just as effective in suppressing postsurgical pain as presurgical administration."( Comparison of preoperative and postoperative diflunisal for suppression of postoperative pain.
Martin, RP; Mosley, RO; Sisk, AL, 1989
)
0.88

Toxicity

ExcerptReferenceRelevance
"The Food and Drug Administration has collected spontaneous reports on adverse events (AE) from manufacturers and individuals."( Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
Tsong, Y, 1995
)
0.29
"Retrospective analysis of adverse event databases."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
"Reports of adverse events submitted to the FDAs Spontaneous Reporting System and the Adverse Event Reporting System from January 1969-December 2000 for these drugs were analyzed according to the number of adverse events reported for each drug per year from the time the drug was approved until December 2000."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
" Various other factors affected spontaneous reporting of adverse events, as peaks in the number of reports were seen numerous times for each drug after the initial 5-year marketing period."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Firstly, PCIS were incubated with 0-200 μM diclofenac (DCF), one of the most intensively studied NSAIDs, to investigate whether they could correctly reflect the toxic mechanisms."( Precision cut intestinal slices are an appropriate ex vivo model to study NSAID-induced intestinal toxicity in rats.
de Graaf, IA; Groothuis, GM; Niu, X; van der Bij, HA, 2014
)
0.4
"Diflunisal-related adverse events included deterioration of renal function and thrombocytopenia resulting in discontinuation of the drug in three patients."( Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.
Ikeda, S; Koyama, J; Morita, H; Sekijima, Y; Tojo, K, 2015
)
2.14

Pharmacokinetics

There are few pharmacokinetic data available on the disposition of diflunisal in patients. This study, therefore, looked at the oral absorption, distribution and elimination of this drug.

ExcerptReferenceRelevance
"There are few pharmacokinetic data available on the disposition of diflunisal in patients; this study, therefore, looked at the oral absorption, distribution and elimination of this drug."( Pharmacokinetics of diflunisal in patients.
Brune, K; Koehler, G; Nuernberg, B, 1991
)
0.84
" No difference was observed in any pharmacokinetic parameter between age-matched healthy subjects and patients with rheumatoid arthritis."( Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
Erikson, LO; Lindholm, L; Melander, A; Odar-Cederlöf, I; Wåhlin-Boll, E, 1989
)
0.5
" Thus, the increase in diflunisal analgesic response in arthritis may be attributed to pharmacokinetic perturbations, resulting from alterations in serum protein binding and not to changes in drug pharmacodynamics."( Diflunisal pharmacodynamics in experimental arthritis in rats.
Kasmerski, L; Walker, JS, 1988
)
2.03
" The plasma elimination half-life was calculated to be 10."( Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys.
Cukierski, M; Hendrickx, AG; Prahalada, S; Robertson, RT; Rowland, JM; Tocco, D, 1987
)
0.52
" The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10."( The influence of diflunisal on the pharmacokinetics of oxazepam.
de Schepper, PJ; Tjandramaga, TB; van Hecken, AM; Verbesselt, R, 1985
)
0.61
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effects of diflunisal on the indomethacin glucuronidation were thus investigated in vitro using human liver microsomes (HLM) and human intestine microsomes (HIM) in order to assess the drug-drug interaction."( In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans.
Kamimura, H; Mano, Y; Usui, T, 2006
)
0.96
" In the current work, a novel solid phase drug-drug co-crystal involving DIF and PZA with molar ratio 1:1 was prepared through the mechanical grinding approach, and vibrational spectroscopic techniques including terahertz time-domain spectroscopy (THz-TDS) and Raman spectroscopy were performed to identify DIF, PZA and their pharmaceutical drug-drug co-crystal."( Solid phase drug-drug pharmaceutical co-crystal formed between pyrazinamide and diflunisal: Structural characterization based on terahertz/Raman spectroscopy combining with DFT calculation.
Du, Y; Hong, Z; Liu, J; Qin, J; Wang, Y; Wu, X; Xue, J, 2020
)
0.79

Bioavailability

Diflunisal is well absorbed from the gastrointestinal tract, is subject to dose-dependent pharmacokinetics (like aspirin), and reaches steady-state levels in a predictable fashion in most persons. In-vivo studies indicated that difl unisal-loaded PHEA microparticles significantly improved the gastric tolerance and oral bioavailability of the drug.

ExcerptReferenceRelevance
" and oral diflunisal doses, the absolute bioavailability was 89."( Buffering the stomach content enhances the absorption of diflunisal in man.
Brune, K; Nuernberg, B,
)
0.78
" Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly, so for the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity."( Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity.
Rainsford, KD, 1986
)
0.27
" Diflunisal is well absorbed from the gastrointestinal tract, is subject to dose-dependent pharmacokinetics (like aspirin), and reaches steady-state levels in a predictable fashion in most persons."( Review of the animal and clinical pharmacology of diflunisal.
Davies, RO,
)
1.29
" We examined the effect of single concomitant doses of three antacids on diflunisal bioavailability under fasting or fed conditions (30 min after finishing a standard meal)."( Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states.
Buntinx, AP; DeSchepper, P; Hall, TL; Huber, PB; Meisinger, MA; Mullie, A; Tjandramaga, TB; Tobert, JA; Yeh, KC, 1981
)
0.75
" No hydrolysis of permethrin was detected; the appearance rate of 3-phenoxybenzyl alcohol with 3-phenoxybenzoic acid corresponded to the absorption rate of the substrate impurities."( No effect of albumin on the dermal absorption rate of hydrocortisone 21-butyrate, permethrin or diflunisal in the isolated, single-pass perfused rabbit ear.
Bast, GE; Kampffmeyer, HG, 1996
)
0.51
" In-vivo studies indicated that diflunisal-loaded PHEA microparticles significantly improved the gastric tolerance and oral bioavailability of the drug in comparison with free diflunisal."( A hydrogel based on a polyaspartamide: characterization and evaluation of in-vivo biocompatibility and drug release in the rat.
Cacciaguerra, S; Giammona, G; Govoni, P; Pitarresi, G; Tomarchio, V, 1997
)
0.58
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" This is to compare the bioavailability of diflunisal-naproxen fixed-dose combination (FDC) with their separate dosage forms."( Comparative in vitro dissolution and in vivo bioavailability of diflunisal/naproxen fixed-dose combination tablets and concomitant administration of diflunisal and naproxen in healthy adult subjects.
El Bedaiwy, HM; Helmy, SA, 2013
)
0.89
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56
"Both pretty low solubility and high membrane permeability of diflunisal (DIF) would affect significantly its oral bioavailability as a typical non-steroidal anti-inflammatory substance."( Solid phase drug-drug pharmaceutical co-crystal formed between pyrazinamide and diflunisal: Structural characterization based on terahertz/Raman spectroscopy combining with DFT calculation.
Du, Y; Hong, Z; Liu, J; Qin, J; Wang, Y; Wu, X; Xue, J, 2020
)
1.03
"Low aqueous solubility and bioavailability is the limiting factor to achieve desired therapeutic efficacy for variety of new and existing drug moieties."( Binary inclusion complexes of diflunisal with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: Preparation and characterization.
Ahmad, J; Asghar, S; Asif, M; Aslam, N; Bashir, M; Iqbal, MS; Irfan, M; Khan, IU; Khan, NR; Saleem, M; Shah, PA; Syed, HK, 2020
)
0.85

Dosage Studied

Diflunisal has a longer duration of action and thus requires less frequent dosing than naproxen. A dosage of 1 g difl unisal was found to be equivalent to 50 drops of tilidine N and to be subjectively well-tolerated.

ExcerptRelevanceReference
" After dosing with DAG, excretion in urine and bile (46% as DAG), hydrolysis (as assessed by recovery of 9% DPG and 8% DS resulting from reconjugation of liberated DF) and rearrangement (17% recovery as isomers of DAG) were important pathways."( Studies on the reactivity of acyl glucuronides--I. Phenolic glucuronidation of isomers of diflunisal acyl glucuronide in the rat.
Dickinson, RG; King, AR, 1991
)
0.5
"04) superior to diflunisal in reducing the pain severity during the first 9 h of treatment; a difference possibly related to the more flexible dosage regimen of ketorolac."( Comparative multiple-dose study of ketorolac tromethamine and diflunisal for pain following orthopaedic surgery.
Fernández-Sabaté, A; Portabella, F,
)
0.72
"This investigation was designed to compare the analgesic effect of the initial dose of a repetitively dosed non-narcotic analgesic with the analgesic effect of a subsequent dose given 3 days later."( Effect of multiple dosing on the analgesic action of diflunisal in rats.
Levy, G; Walker, JS, 1990
)
0.53
" Formation of DF-plasma protein adducts in vivo was also found in rats and humans dosed with DF."( Reactivity of diflunisal acyl glucuronide in human and rat plasma and albumin solutions.
Dickinson, RG; Watt, JA, 1990
)
0.64
" After one-visit nonsurgical endodontic therapy, 100 patients with asymptomatic teeth having either vital-inflamed pulp, pulpal necrosis, or pulpal necrosis with periapical radiolucent lesion were randomly given either prophylactic diflunisal (two tablets immediately at the conclusion of the visit, then four tablets to be taken in the schedule of one every 8 to 12 hours for pain if needed) or on-demand diflunisal (same dosage schedule; pills to be taken only if needed)."( Comparison of prophylactic and on-demand diflunisal for pain management of patients having one-visit endodontic therapy.
Esposito, JV; Furst, ML; Morse, DR, 1990
)
0.73
" The dosage of diflunisal was 500 mg twice daily (d-group) and the dosage of indomethacin 50 mg three times daily (i-group)."( Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago.
Orava, S, 1986
)
0.89
" In addition, diflunisal has a longer duration of action and thus requires less frequent dosing than naproxen."( Comparison of diflunisal and naproxen in the management of acute low back strain.
Aghababian, RV; Heifetz, IN; Volturo, GA, 1986
)
0.99
" It is generally stated that there is only slight impairment of coagulation at the recommended dosage of diflunisal; however, only a few multidose studies have been conducted, most being single dose studies."( The effects of diflunisal on bleeding time and platelet aggregation in a multidose study.
Chapman, PJ; Macleod, AW, 1987
)
0.84
" The dosage of diflunisal could be increased to a maximum of 1 gm daily during the open-label phase."( Comparison of diflunisal and aspirin in long-term treatment of patients with rheumatoid arthritis.
Shackleford, RW; Turner, RA; Whipple, JP, 1986
)
0.98
" These data demonstrate that diflunisal is not teratogenic in cynomolgus monkeys over a dosage range of 20 to 80 mg/kg/day."( Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys.
Cukierski, M; Hendrickx, AG; Prahalada, S; Robertson, RT; Rowland, JM; Tocco, D, 1987
)
0.81
" Despite great differences in dosage and half-life, the active test substances must be regarded as equipment."( [A controlled clinical single-dose comparative study of suprofen and diflunisal].
Arabin, G; Honig, WJ; van Ochten, J, 1983
)
0.5
" These same dosage levels also caused a severe maternal hemolytic anemia following a dramatic decrease in erythrocyte ATP levels."( Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits.
Allen, HL; Bokelman, DL; Clark, RL; Cohen, SM; James, ML; Minsker, DH; Robertson, RT; Tocco, DJ, 1984
)
1.71
" A dosage of 1 g diflunisal was found to be equivalent to 50 drops of tilidine N and to be subjectively well-tolerated."( [Comparison of diflunisal and tilidine in tumor pain].
Brückle, W; Lydtin, H, 1984
)
0.96
" Each dose was given for 14 days and diflunisal apparent oral clearance and serum urate was measured on the last day of each dosing regimen."( Diflunisal disposition and hypouricemic response in osteoarthritis.
Bertouch, J; Brooks, PM; Harrington, BJ; Meffin, PJ; Veenendaal, JR, 1983
)
1.98
" The results of the study showed Diflunisal in an average dosage of 500 to 1000 mg per day to be a useful drug in the treatment of rheumatoid arthritis not least due to the negligible side effects."( [Comparison of the efficacy of diflunisal and acetylsalicylic acid in rheumatoid arthritis (author's transl)].
Fasching, U, 1981
)
0.83
"The effect of the non-steroidal analgesic diflunisal on platelet aggregation and clinical haemorrhage at a dosage 250 mg twice or 3-times daily, sufficient to relieve musculo-skeletal pain and other painful conditions, was studied in 15 patients and 5 normal subjects."( Platelet aggregation in patients treated with diflunisal.
Ghosh, ML; Tingle, A, 1980
)
0.78
" T 1/2 values after cessation of dosing were about 5-10 hr."( Studies on the reactivity of acyl glucuronides--IV. Covalent binding of diflunisal to tissues of the rat.
Dickinson, RG; King, AR, 1993
)
0.52
" In this study, we compared the extent and pattern of covalent adduct formation in plasma and livers of rats dosed with the nonsteroidal anti-inflammatory drugs (NSAIDs) zomepirac (ZP) and diflunisal (DF), the hypolipidemic agent clofibric acid (CA), and the anti-epileptic agent valproic acid (VPA)."( Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
Bailey, MJ; Dickinson, RG,
)
0.32
" Diflunisal was given at the dosage of 500 mg perorally twice a day, and dipyrone was given at the dosage of 500 mg perorally three times a day."( A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study.
Firat, D; Güllü, IH; Savaş, C; Tekuzman, G; Yalçin, S, 1998
)
1.46
" On day 7 of each dosing phase, serial blood samples and all urine passed over the 12-h inter-dosing interval were collected."( Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
Addison, RS; Dickinson, RG; Eadie, MJ; Hooper, WD; Parker-Scott, SL, 2000
)
0.57
" Rats were dosed orally with diflunisal (DF), its acyl glucuronide (DAG) and a mixture of rearrangement isomers (iso-DAG) at 10 mg DF equivalents/kg."( Rearrangement of diflunisal acyl glucuronide into its beta-glucuronidase-resistant isomers facilitates transport through the small intestine to the colon of the rat.
Dickinson, RG; King, AR, 2001
)
0.94
" The above method was applied to determine the plasma concentration of difunisal in three human volunteers after a single oral dosage of 300 mg."( [Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction].
Gao, L; Liu, W; Xing, J, 1998
)
0.63
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" This property may be useful when regular dosing is needed, or when taking several doses of a shorter acting analgesic is impractical."( Single dose oral diflunisal for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA; Wasey, JO, 2010
)
0.7
" The development of drug-CD complexes as solids allows for potential advantages in dosage form design, such as the preparation of layered formulations, and it also can yield improvements in chemical and physical stability."( 2D solid-state NMR analysis of inclusion in drug-cyclodextrin complexes.
Strohmeier, M; Vogt, FG, 2012
)
0.38
" This is to compare the bioavailability of diflunisal-naproxen fixed-dose combination (FDC) with their separate dosage forms."( Comparative in vitro dissolution and in vivo bioavailability of diflunisal/naproxen fixed-dose combination tablets and concomitant administration of diflunisal and naproxen in healthy adult subjects.
El Bedaiwy, HM; Helmy, SA, 2013
)
0.89
" We unexpectedly discover a new class of aggregating ligands that exhibit negligible interactions with proteins but act as competitive sinks for the free inhibitor, resulting in bell-shaped dose-response curves."( Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
Ahmed, R; Boulton, S; Cheng, X; Melacini, G; Selvaratnam, R; Van, K, 2019
)
0.51
" The presence of BPL could significantly affect the dose of DIF in its dosage forms; hence it is crucial to determine DIF and BPL in each other's presence."( Separation and Determination of Diflunisal and its Impurity by Two Chromatographic Methods: TLC-Densitometry and HPLC.
El Ghobashy, MR; Farid, NF; Moatamed, RS; Naguib, IA, 2021
)
0.9
" Herein, we report the diflunisal plasma concentrations measured by extraction, reversed phase HPLC separation, and fluorescence detection after long-term 250 mg BID oral dosing in two groups: a placebo-controlled diflunisal clinical trial group and an open-label Japanese polyneuropathy treatment cohort."( Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Berk, JL; Jäger, M; Kelly, JW; Kline, GM; Nelson, LT; Powers, ET; Sekijima, Y; Tsai, FJ, 2023
)
1.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
monohydroxybenzoic acidAny hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Diflunisal Action Pathway2967

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.19950.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency21.96430.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency22.10610.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency22.10610.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency24.13200.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency20.68750.007215.758889.3584AID1224835; AID588342; AID624030
SMAD family member 2Homo sapiens (human)Potency9.58370.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency9.58370.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency23.26260.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency5.55560.000221.22318,912.5098AID743035; AID743036; AID743053
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.19690.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency22.04120.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.69030.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.98560.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.40490.001530.607315,848.9004AID1224841; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency11.88230.375827.485161.6524AID743217; AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.76640.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency23.26010.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency18.83220.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency10.68220.023723.228263.5986AID743223
activating transcription factor 6Homo sapiens (human)Potency13.44810.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.535419.739145.978464.9432AID1159509
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency6.30960.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.08220.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.06310.00798.23321,122.0200AID2551
lamin isoform A-delta10Homo sapiens (human)Potency5.09100.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency38.90180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency2.01990.002319.595674.0614AID651631
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency6.30961.584913.004325.1189AID927
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)Ki34.00000.00000.37564.9000AID1660990
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)3.38000.00582.14107.9000AID349140
Carbonic anhydrase 1Homo sapiens (human)Ki8.45000.00001.372610.0000AID349142
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)2.70000.00021.10608.3000AID349141
Carbonic anhydrase 2Homo sapiens (human)Ki9.37000.00000.72369.9200AID349145
TransthyretinHomo sapiens (human)IC50 (µMol)7.10000.16004.292110.0000AID1074430; AID1614588; AID1755162; AID1774080
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)0.85000.27004.53069.9000AID681160
2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)Ki2.56002.56002.56002.5600AID1744124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
electroneutral potassium-chloride cotransporter KCC2Homo sapiens (human)EC50 (µMol)3.25000.48101.53032.3100AID1736
TransthyretinHomo sapiens (human)EC50 (µMol)5.60005.60007.54298.6000AID1169291
TransthyretinHomo sapiens (human)Kd1.77700.00301.348210.0000AID1239060; AID1386000; AID1605604; AID1705462; AID1705465; AID1774086
AlbuminHomo sapiens (human)Kd2.11510.08933.31358.0000AID1450923; AID327170
High mobility group protein B1Homo sapiens (human)Kd1,600.00000.02400.63101.0000AID1773958
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)Kd10.07500.06000.17170.3800AID210956
TransthyretinHomo sapiens (human)Kd21.10001.10002.82676.1800AID210957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (292)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
myeloid dendritic cell activationHigh mobility group protein B1Homo sapiens (human)
activation of innate immune responseHigh mobility group protein B1Homo sapiens (human)
dendritic cell chemotaxisHigh mobility group protein B1Homo sapiens (human)
inflammatory response to antigenic stimulusHigh mobility group protein B1Homo sapiens (human)
regulation of tolerance inductionHigh mobility group protein B1Homo sapiens (human)
regulation of T cell mediated immune response to tumor cellHigh mobility group protein B1Homo sapiens (human)
DNA topological changeHigh mobility group protein B1Homo sapiens (human)
double-strand break repair via nonhomologous end joiningHigh mobility group protein B1Homo sapiens (human)
DNA recombinationHigh mobility group protein B1Homo sapiens (human)
autophagyHigh mobility group protein B1Homo sapiens (human)
inflammatory responseHigh mobility group protein B1Homo sapiens (human)
signal transductionHigh mobility group protein B1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHigh mobility group protein B1Homo sapiens (human)
positive regulation of autophagyHigh mobility group protein B1Homo sapiens (human)
negative regulation of RNA polymerase II transcription preinitiation complex assemblyHigh mobility group protein B1Homo sapiens (human)
neuron projection developmentHigh mobility group protein B1Homo sapiens (human)
heterochromatin formationHigh mobility group protein B1Homo sapiens (human)
regulation of restriction endodeoxyribonuclease activityHigh mobility group protein B1Homo sapiens (human)
DNA geometric changeHigh mobility group protein B1Homo sapiens (human)
positive regulation of mismatch repairHigh mobility group protein B1Homo sapiens (human)
negative regulation of type II interferon productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-1 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-10 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-12 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-6 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-8 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of tumor necrosis factor productionHigh mobility group protein B1Homo sapiens (human)
V(D)J recombinationHigh mobility group protein B1Homo sapiens (human)
positive regulation of toll-like receptor 9 signaling pathwayHigh mobility group protein B1Homo sapiens (human)
T-helper 1 cell activationHigh mobility group protein B1Homo sapiens (human)
positive regulation of activated T cell proliferationHigh mobility group protein B1Homo sapiens (human)
positive regulation of apoptotic processHigh mobility group protein B1Homo sapiens (human)
apoptotic cell clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processHigh mobility group protein B1Homo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell differentiationHigh mobility group protein B1Homo sapiens (human)
positive regulation of DNA bindingHigh mobility group protein B1Homo sapiens (human)
positive regulation of MAPK cascadeHigh mobility group protein B1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHigh mobility group protein B1Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationHigh mobility group protein B1Homo sapiens (human)
T-helper 1 cell differentiationHigh mobility group protein B1Homo sapiens (human)
innate immune responseHigh mobility group protein B1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
positive regulation of JNK cascadeHigh mobility group protein B1Homo sapiens (human)
positive regulation of viral entry into host cellHigh mobility group protein B1Homo sapiens (human)
positive chemotaxisHigh mobility group protein B1Homo sapiens (human)
positive regulation of DNA ligationHigh mobility group protein B1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh mobility group protein B1Homo sapiens (human)
cellular response to lipopolysaccharideHigh mobility group protein B1Homo sapiens (human)
positive regulation of monocyte chemotaxisHigh mobility group protein B1Homo sapiens (human)
neutrophil clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationHigh mobility group protein B1Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionHigh mobility group protein B1Homo sapiens (human)
negative regulation of apoptotic cell clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of dendritic cell differentiationHigh mobility group protein B1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
tryptophan catabolic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
negative regulation of quinolinate biosynthetic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
picolinic acid biosynthetic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
regulation of 'de novo' NAD biosynthetic process from tryptophan2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
secondary metabolic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (113)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
four-way junction DNA bindingHigh mobility group protein B1Homo sapiens (human)
bubble DNA bindingHigh mobility group protein B1Homo sapiens (human)
transcription cis-regulatory region bindingHigh mobility group protein B1Homo sapiens (human)
lipopolysaccharide bindingHigh mobility group protein B1Homo sapiens (human)
phosphatidylserine bindingHigh mobility group protein B1Homo sapiens (human)
damaged DNA bindingHigh mobility group protein B1Homo sapiens (human)
double-stranded DNA bindingHigh mobility group protein B1Homo sapiens (human)
single-stranded DNA bindingHigh mobility group protein B1Homo sapiens (human)
transcription coactivator activityHigh mobility group protein B1Homo sapiens (human)
transcription corepressor activityHigh mobility group protein B1Homo sapiens (human)
RNA bindingHigh mobility group protein B1Homo sapiens (human)
cytokine activityHigh mobility group protein B1Homo sapiens (human)
integrin bindingHigh mobility group protein B1Homo sapiens (human)
protein bindingHigh mobility group protein B1Homo sapiens (human)
DNA binding, bendingHigh mobility group protein B1Homo sapiens (human)
lyase activityHigh mobility group protein B1Homo sapiens (human)
C-X-C chemokine bindingHigh mobility group protein B1Homo sapiens (human)
chemoattractant activityHigh mobility group protein B1Homo sapiens (human)
receptor ligand activityHigh mobility group protein B1Homo sapiens (human)
RAGE receptor bindingHigh mobility group protein B1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHigh mobility group protein B1Homo sapiens (human)
DNA polymerase bindingHigh mobility group protein B1Homo sapiens (human)
supercoiled DNA bindingHigh mobility group protein B1Homo sapiens (human)
DNA-binding transcription factor bindingHigh mobility group protein B1Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
aminocarboxymuconate-semialdehyde decarboxylase activity2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
protein binding2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
zinc ion binding2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
hydrolase activity2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceHigh mobility group protein B1Homo sapiens (human)
condensed chromosomeHigh mobility group protein B1Homo sapiens (human)
extracellular regionHigh mobility group protein B1Homo sapiens (human)
extracellular spaceHigh mobility group protein B1Homo sapiens (human)
nucleusHigh mobility group protein B1Homo sapiens (human)
nucleoplasmHigh mobility group protein B1Homo sapiens (human)
endosomeHigh mobility group protein B1Homo sapiens (human)
endoplasmic reticulumHigh mobility group protein B1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentHigh mobility group protein B1Homo sapiens (human)
cell surfaceHigh mobility group protein B1Homo sapiens (human)
secretory granule lumenHigh mobility group protein B1Homo sapiens (human)
ficolin-1-rich granule lumenHigh mobility group protein B1Homo sapiens (human)
transcription repressor complexHigh mobility group protein B1Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexHigh mobility group protein B1Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
cytosol2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
cytosol2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
cytoplasm2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (309)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1774081Stabilization of TTR V3OM mutant (unknown origin) assessed as suppression of TTR tetramer dissociation at 1 to 10 uM incubated for 9 days by glutaraldehyde cross-linking assay based SDS-PAGE analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1413213Potentiation of erythromycin-induced antibacterial activity against Escherichia coli ATCC 43894 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413190Potentiation of geneticin-induced antibacterial activity against Streptococcus pyogenes ATCC 14289 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1276647Cytotoxicity against human Mahlavu cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID349142Inhibition of human carbonic anhydrase 1 esterase activity by noncompetitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1705462Binding affinity to wild type TTR (unknown origin) expressed in Escherichia coli BL21/DE3 by Circular dichroism spectroscopy2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID1136207Inhibition of PG synthase (unknown origin)1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1239061Binding affinity to TTR in human plasma assessed as protein stabilization preincubated for 1 hr followed by urea-mediated denaturation by Western blot analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1614577Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 1.5 uM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1413170Antiinflammatory activity in human PBMC-differentiated macrophages assessed as inhibition of LPS-induced TNFalpha production at 0.01 to 10 uM measured after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1774080Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID624661Inhibition of mycophenolic acid (0.5 mM) glucuronidation by human kidney microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1136198Plasma concentration in human at 250 mg/kg, po after 2 hrs1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1450923Binding affinity to human serum albumin2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1413195Potentiation of geneticin-induced antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1136213Analgesic activity in po dosed rat by hyperesthesia test1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1276646Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1276651Induction of apoptosis in human HuH7 cells assessed as DNA fragmentation at IC50 after 72 hrs by hoechst 33258 staining based fluorescence microscopy2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID1705465Stabilization of TTR V30M mutant (unknown origin) assessed as inhibition of protein-mediated amyloid fibril formation2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1614596Stabilization of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as formation of TTR tetramer band formation at 2 uM after 4 mins by SDS-PAGE analysis based glutaraldehyde cross-linking assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1413203Potentiation of erythromycin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1413207Potentiation of tetracycline-induced antibacterial activity against Pseudomonas aeruginosa ATCC BAA-2108 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1136202Drug excretion in human urine after 96 hrs1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID681160TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID1413181Toxicity in Enterococcus faecium ATCC 700221 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1413206Potentiation of ciprofloxacin-induced antibacterial activity against Pseudomonas aeruginosa ATCC BAA-2108 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413177Induction of prostaglandin production in human PBMC-differentiated macrophages after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID327169Apparent permeability across parallel artificial membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID89369Transthyretin (TTR) amyloidogenesis inhibition activity by employing an acid-mediated (pH 4.4) WTTTR amyloid fibril formation assay, at 7.2 uM conc.2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID1413188Potentiation of erythromycin-induced antibacterial activity against Staphylococcus aureus ATCC 33592 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1614588Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as BC50 for ANS binding to TTR at 5 uM in presence of 150 mM Na+ by fluorescence-based assay (Rvb = 3 uM)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1529187Binding affinity to human serum albumin assessed as change in dissociation constant pKa2 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID574422Inhibition of wild type-TTR expressed in Escherichia coli assessed as amyloid fibril formation at pH 4.4 at 7. 2 uM after 72 hrs by acid-mediated aggregation assay relative to control2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1413196Potentiation of ciprofloxacin-induced antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413192Potentiation of tetracycline-induced antibacterial activity against Streptococcus pyogenes ATCC 14289 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID349140Inhibition of human carbonic anhydrase 1 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1386009Binding affinity to transthyretin in human serum assessed as protein occupancy at 2:1 compound to TTR ratio after 72 hrs by fluorescent probe exclusion assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1901404Destabilization of human LDH-1expressed in Escherichia coli assessed as change in melting temperature at 1 mM heated for 3 mins by NanoDSF assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID1413209Potentiation of methicillin-induced antibacterial activity against Escherichia coli ATCC 43894 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1386013Cmax in human at 250 mg bid2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1413174Induction of TNFalpha production in human PBMC-differentiated macrophages after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID210956The first dissociation constant for binding to WT TTR determined by isothermal titration calorimetry (25 C, pH 8.0)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1901397Stabilization of Red-dye-NHS fluorescent-labeled human LDH-Htr expressed in Escherichia coli assessed as dissociation constant by MST assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1054847Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis at 40 uM after 30 mins by turbidimetric assay relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1413176Induction of IL-1beta production in human PBMC-differentiated macrophages after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1276645Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID1386007Binding affinity to transthyretin (unknown origin) assessed as free TdeltaS changes by ITC method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1276649Cytotoxicity against human SNU475 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID1605604Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as dissociation constant for TTR-amyloid beta (12 to 28) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyloid beta (12 t
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1054848Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis after 30 mins by turbidimetric assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1605603Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as fibril formation at 50 uM pre-incubated with transthyretin before amyloid beta (1 to 42) addition by ThT fluorescence assay (Rvb = 25 +/- 1%)
AID624662Inhibition of mycophenolic acid (1 mM) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1413185Potentiation of geneticin-induced antibacterial activity against Staphylococcus aureus ATCC 33592 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1901398Destabilization of Red-dye-NHS fluorescent-labeled human LDH-5 expressed in Escherichia coli assessed as dissociation constant by MST assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID639952Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1413205Potentiation of geneticin-induced antibacterial activity against Pseudomonas aeruginosa ATCC BAA-2108 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1169294Inhibition of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation at 20 uM by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1413194Potentiation of methicillin-induced antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1136205Analgesic activity in po dosed dog knee joint pain model1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1413182Toxicity in Pseudomonas aeruginosa ATCC BAA-2108 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1413191Potentiation of ciprofloxacin-induced antibacterial activity against Streptococcus pyogenes ATCC 14289 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID443729Antiinflammatory activity against assessed as inhibition of carrageenan-induced foot paw edema in po dosed rat after 3 hrs2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory ac
AID1136210Toxicity in rat assessed as gastric hemorrhage at 256 mg/kg, po1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1598718Binding affinity to Triton-X 100 assessed as change in chemical shift at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID1136206Analgesic activity in po dosed rat assessed as inhibition of adjuvant-induced arthritis pain1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID772085Inhibition of transthyretin (unknown origin) aggregation at 2 mol equiv measured at 36 hrs by congo red assay relative to control2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Designed Trpzip-3 β-Hairpin Inhibits Amyloid Formation in Two Different Amyloid Systems.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1724082Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) assessed as fibril formation at 7.2 uM preincubated for 30 mins with transthyretin followed by measuring after 72 hrs maintaining pH of 4.4 by UV-Visible spectrophotome2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID89368Transthyretin (TTR) amyloidogenesis inhibition activity by employing an acid-mediated (pH 4.4) WTTTR amyloid fibril formation assay, at 3.6 uM conc.2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID1074430Inhibition of transthyretin V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of sodium acetate-mediated aggregation preincubated for 30 mins followed by sodium acetate addition measured after 96 hrs by thioflavin T assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Crystal structures of human transthyretin complexed with glabridin.
AID1054846Binding affinity to human recombinant TTR Y78F mutant after 5 mins by isothermal titration calorimetry2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1413186Potentiation of ciprofloxacin-induced antibacterial activity against Staphylococcus aureus ATCC 33592 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID396471Analgesic activity in Kunming mouse assessed as inhibition of acetic acid-induced writhing response at 40 mg/kg, po2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Synthesis and biological evaluation of amide derivatives of diflunisal as potential anti-inflammatory agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1413180Toxicity in Klebsiella pneumoniae ATCC 13883 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1774086Binding affinity to TTR V30M mutant (unknown origin) by isothermal titration calorimetry2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136212Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1386005Binding affinity to transthyretin (unknown origin) assessed as free energy changes by ITC method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID349145Inhibition of human carbonic anhydrase 2 esterase activity by non-competitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1413175Induction of IL-8 production in human PBMC-differentiated macrophages after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1386006Binding affinity to transthyretin (unknown origin) assessed as free enthalpy changes by ITC method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1413189Potentiation of methicillin-induced antibacterial activity against Streptococcus pyogenes ATCC 14289 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413187Potentiation of tetracycline-induced antibacterial activity against Staphylococcus aureus ATCC 33592 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413199Potentiation of methicillin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID681781TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Diflunisal: 1000 uM) in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID1136199Plasma concentration in human at 500 mg/kg, po after 2 hrs1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1413172Antiinflammatory activity in human PBMC-differentiated macrophages assessed as inhibition of LPS-induced IL-1beta production at 0.01 to 10 uM measured after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1413165Cytotoxicity against human PBMC-differentiated macrophages treated for 24 hrs followed by compound washout and measured after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID574423Displacement of 4-fluorophenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzoate from recombinant TTR assessed as fluorescence at 37 degC after 3 hrs2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1614578Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 5 uM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1413208Potentiation of erythromycin-induced antibacterial activity against Pseudomonas aeruginosa ATCC BAA-2108 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1386015Dissociation constant, pKa of the compound2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1169291Inhibition of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1413212Potentiation of tetracycline-induced antibacterial activity against Escherichia coli ATCC 43894 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1486519Binding affinity to transthyretin in human blood plasma assessed as plasma binding selectivity by measuring stoichiometry of small molecule bound to TTR incubated for 24 hrs at 37 degC by RP-HPLC2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1276650Induction of apoptosis in human HuH7 cells assessed as nuclear condensation at IC50 after 72 hrs by hoechst 33258 staining based fluorescence microscopy2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1413201Potentiation of ciprofloxacin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1136204Antipyretic activity in po dosed rat1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1276644Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1744124Competitive inhibition of human ACMSD using ACMS substrate by spectrometry2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1136196Antiinflammatory activity against carrageenan-induced foot edema in rat administered via gastric gavage1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1413202Potentiation of tetracycline-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID396474Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Synthesis and biological evaluation of amide derivatives of diflunisal as potential anti-inflammatory agents.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1413200Potentiation of geneticin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413211Potentiation of ciprofloxacin-induced antibacterial activity against Escherichia coli ATCC 43894 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 ciprofloxacin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413210Potentiation of geneticin-induced antibacterial activity against Escherichia coli ATCC 43894 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 geneticin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID396470Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 40 mg/kg, po2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Synthesis and biological evaluation of amide derivatives of diflunisal as potential anti-inflammatory agents.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID574424Displacement of S-phenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzothioate from human TTR assessed as fluorescence at 37 degC after 3 hrs2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID1413171Antiinflammatory activity in human PBMC-differentiated macrophages assessed as inhibition of LPS-induced IL-8 production at 0.01 to 10 uM measured after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1386017Binding affinity to transthyretin (unknown origin) in human serum assessed as protein occupancy at 20 uM by fluorescent probe exclusion assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1136203Analgesic activity in po dosed rat assessed as inhibition of yeast-induced inflammatory pain1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1276648Cytotoxicity against human FOCUS cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
AID1413204Potentiation of methicillin-induced antibacterial activity against Pseudomonas aeruginosa ATCC BAA-2108 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1901400Destabilization of Red-dye-NHS fluorescent-labeled human LDH-1 expressed in Escherichia coli assessed as dissociation constant by MST assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID1614595Stabilization of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as formation of TTR tetramer band formation at 1 uM after 4 mins by SDS-PAGE analysis based glutaraldehyde cross-linking assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1413178Toxicity in Staphylococcus aureus ATCC 33592 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID210954Ability to bind TTR selectively over all other proteins in human blood plasma (equiv bound)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID210957The second dissociation constant for binding to WT TTR determined by isothermal titration calorimetry (25 C, pH 8.0)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1386008Binding affinity to transthyretin (unknown origin) in pH 7.4 PBS buffer assessed as protein occupancy at 1:1 compound to TTR ratio by fluorescent probe exclusion assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1901402Stabilization of human LDH-Htr expressed in Escherichia coli assessed as change in melting temperature at 1 mM heated for 3 mins by NanoDSF assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID349141Inhibition of human carbonic anhydrase 2 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1413193Potentiation of erythromycin-induced antibacterial activity against Streptococcus pyogenes ATCC 14289 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413183Toxicity in Escherichia coli ATCC 43894 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1773958Binding affinity to full-length N-terminal 6His-tagged HMGB1 (unknown origin) by NMR spectra2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction.
AID1614576Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 0.5 uM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1413197Potentiation of tetracycline-induced antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 tetracycline2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136209Toxicity in po dosed rat assessed as intestinal perforating ulcer1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1239060Binding affinity to TTR (unknown origin) by isothermal titration calorimetric analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
AID1486518Inhibition of acid-induced wild type transthyretin (unknown origin) aggregation expressed in Escherichia coli pre-incubated for 30 mins before acid addition and further incubated for 72 hrs at 37 degC under dark conditions by UV-Vis spectrophotometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID540235Phospholipidosis-negative literature compound
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1386000Binding affinity to transthyretin (unknown origin) by ITC method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1901403Destabilization of human LDH-5 expressed in Escherichia coli assessed as change in melting temperature at 1 mM heated for 3 mins by NanoDSF assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
AID1413179Toxicity in Streptococcus pyogenes ATCC 14289 up to 32 uM measured after 16 hrs2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1413198Potentiation of erythromycin-induced antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1413184Potentiation of methicillin-induced antibacterial activity against Staphylococcus aureus ATCC 33592 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 methicillin2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID327170Binding affinity to human serum albumin by PAMPA method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1386019Binding affinity to transthyretin (unknown origin) in human serum assessed as protein stabilization at 10 uM in pH 7.4 urea buffer by Western blot2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1413169Antiinflammatory activity in human PBMC-differentiated macrophages assessed as lowest concentration required to show at least 25% inhibition of LPS-induced prostaglandin production measured after 24 hrs by ELISA2018MedChemComm, Jun-01, Volume: 9, Issue:6
Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1386010Binding affinity to transthyretin in human serum assessed as protein stabilization at 2:1 compound to TTR ratio after 72 hrs by Western blot2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1598719Binding affinity to Triton-X 100 assessed as line broadening at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID295863Antinociceptive activity against mouse assessed as paw withdrawal latency at 50 mg/kg, po after 60 mins by hot plate test2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID243647In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive2004Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
AID295862Antiinflammatory activity against BALB/c mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1744125Inhibition of human ACMSD using ACMS substrate by spectrometry2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (543)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990221 (40.70)18.7374
1990's81 (14.92)18.2507
2000's77 (14.18)29.6817
2010's115 (21.18)24.3611
2020's49 (9.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.04 (24.57)
Research Supply Index6.60 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index102.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials129 (21.32%)5.53%
Reviews41 (6.78%)6.00%
Case Studies29 (4.79%)4.05%
Observational0 (0.00%)0.25%
Other406 (67.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Diflunisal on Familial Amyloidosis [NCT00294671]Phase 2/Phase 3130 participants (Actual)Interventional2006-02-28Completed
AN OPEN-LABEL, SINGLE-SEQUENCE, CROSSOVER STUDY TO INVESTIGATE THE EFFECTS OF UGT1A9 INHIBITOR DIFLUNISAL, AT STEADY-STATE, ON PHARMACOKINETICS OF A SINGLE DOSE OF BMS-986165 IN HEALTHY MALE AND FEMALE VOLUNTEERS [NCT04113668]Phase 148 participants (Actual)Interventional2019-10-01Completed
A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin. [NCT00506298]Phase 2150 participants (Anticipated)Interventional2007-07-31Completed
Pilot Study of Diflunisal in HIV-infected Adults [NCT01676363]Phase 48 participants (Actual)Interventional2013-03-31Terminated(stopped due to Insufficient enrollment.)
"The Effect of Diflunisal on Familial Transthyretin Amyloidosis: An Open Label Extension Study of the Diflunisal Trial (IND 68092), and an Open Label Observational Study on Previously Untreated Patients With Familial Transthyretin Amyloidosis." [NCT01432587]55 participants (Actual)Observational2011-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00294671 (5) [back to overview]Kumamoto Neurologic Scale;
NCT00294671 (5) [back to overview]Modified Body Mass Index (mBMI);
NCT00294671 (5) [back to overview]Neurologic Impairment Score + 7 (NIS+7)
NCT00294671 (5) [back to overview]Quality of Life Questionnaire: SF-36 Mental Component Score
NCT00294671 (5) [back to overview]Quality of Life Questionnaire: SF-36 Physical Component Score

Kumamoto Neurologic Scale;

Change from baseline of the Kumamoto Score (0-102 points, increasing with disease severity), a clinical neurologic scale of motor, sensory, and autonomic function combined with heart and kidney end organ measures developed to track disease progression in Familial Amyloid Polyneuropathy (ATTR-FAP) (NCT00294671)
Timeframe: Baseline, 1 and 2 years

,
Interventionunits on a scale (Mean)
Change from baseline to 2 yearsChange from baseline to 1 year
Diflunisal3.11.9
Placebo8.04.1

[back to top]

Modified Body Mass Index (mBMI);

The product of body mass index (BMI) and serum albumin level (g/L) [kg/M2xg/L]. (NCT00294671)
Timeframe: Baseline, 1 and 2 years

,
Interventionkg/M2xg/L (Mean)
Change from baseline to 2 yearsChange from baseline to 1 year
Diflunisal-33.7-18.7
Placebo-67.9-38.5

[back to top]

Neurologic Impairment Score + 7 (NIS+7)

The primary endpoint, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurologic deficits) to 270 points (no detectable peripheral nerve function). (NCT00294671)
Timeframe: Baseline, 1 and 2 years

,
Interventionunits on a scale (Mean)
Change from baseline to 2 yearsChange from baseline to 1 year
Diflunisal8.26.2
Placebo26.312.5

[back to top]

Quality of Life Questionnaire: SF-36 Mental Component Score

The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of mental component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years

,
Interventionunits on a scale (Mean)
Change from baseline to 2 yearsChange from baseline to 1 year
Diflunisal3.52.5
Placebo-0.90.8

[back to top]

Quality of Life Questionnaire: SF-36 Physical Component Score

The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of physical component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years

,
Interventionunits on a scale (Mean)
Change from baseline to 2 yearsChange from baseline to 1 year
Diflunisal1.20.7
Placebo-4.9-1.9

[back to top]